Skip to main content
. 2001 Feb;51(2):174–176. doi: 10.1111/j.1365-2125.2001.01323.x

Table 2.

Use of ASA and Other Salicylates Among 373 Cases of SCAR and 1720 Controls According to Type of Preparation and Disease Classification.

Class Drug Type of preparation Cases Controls Crude relative risk estimate Multivariate relative risk estimate (95% confidence interval)
SJS ASA Single ingredient 12 92 1.6 1.2 (0.5,2.6)
Combination 2 12
Other salicylates Single ingredient 3 26 1.4 1.4 (0.3,4.6)*
Combination 1 3
Overlap ASA Single ingredient 7 92 1.3 1.7 (0.6,4.6)
SJS/TEN Combination 4 12 5.7 3.6 (0.6,21)
Other salicylates Single ingredient 3 26 2.0 2.0 (0.4,6.6)*
Combination 1 3
TEN ASA Single ingredient 12 92 2.1 1.5 (0.6,3.9)
Combination 0 12
Other salicylates Single ingredient 2 26
Combination 0 3
*

Crude estimate.